Potential PDE4B inhibitors as promising candidates against SARS‐CoV‐2 infection
Biomolecular Concepts · 2023
DOI: 10.1515/bmc-2022-0033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecular Concepts, 2023. Verfasst von Federica Giuzio und 10 weiteren Autor:innen. Beteiligte Einrichtung: International PhD Programme 'Sciences', Department of Science, University of Basilicata, Viale dell'Ateneo Lucano n.10, 85100 Potenza, Italy. Hauptthemen laut MEDLINE: COVID-19, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is an RNA virus belonging to the coronavirus family responsible for coronavirus disease 2019 (COVID-19). It primarily affects the pulmonary system, which is the target of chronic obstructive pulmonary disease (COPD), for which many new compounds have been developed. In this study, phosphodiesterase 4 (PDE4) inhibitors are being investigated. The inhibition of PDE4 enzyme produces anti-inflammatory and bronchodilator effects in the lung by inducing an increase in cAMP concentrations. Piclamilast and rolipram are known selective inhibitors of PDE4, which are unfortunately endowed with common side effects, such as nausea and emesis. The selective inhibition of the phosphodiesterase 4B (PDE4B) subtype may represent an intriguing technique for combating this highly contagious disease with fewer side effects. In this article, molecular docking studies for the selective inhibition of the PDE4B enzyme have been carried out on 21 in-house compounds. The compounds were docked into the pocket of the PDE4B catalytic site, and in most cases, they were almost completely superimposed onto piclamilast. Then, in order to enlarge our study, drug-likeness prediction studies were performed on the compounds under study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International PhD Programme 'Sciences', Department of Science, University of Basilicata, Viale dell'Ateneo Lucano n.10, 85100 Potenza, Italy.
- Department of Science, University of Basilicata, 85100 Potenza, Italy.
- Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70126 Bari, Italy.
- School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.
Zitieren
APA
Giuzio, F., Bonomo, M. G., Catalano, A., Infantino, V., Salzano, G., Monné, M., Geronikaki, A., Petrou, A., Aquaro, S., Sinicropi, M. S., & Saturnino, C. (2023). Potential PDE4B inhibitors as promising candidates against SARS‐CoV‐2 infection. Biomolecular Concepts. https://doi.org/10.1515/bmc-2022-0033
Vancouver
Giuzio F, Bonomo MG, Catalano A, Infantino V, Salzano G, Monné M, et al. Potential PDE4B inhibitors as promising candidates against SARS‐CoV‐2 infection. Biomolecular Concepts. 2023. doi:10.1515/bmc-2022-0033
BibTeX
@article{Giuzio2023,
author = {Giuzio, Federica and Bonomo, Maria Grazia and Catalano, Alessia and Infantino, Vittoria and Salzano, Giovanni and Monné, Magnus and Geronikaki, Athina and Petrou, Anthi and Aquaro, Stefano and Sinicropi, Maria Stefania and Saturnino, Carmela},
title = {Potential PDE4B inhibitors as promising candidates against SARS‐CoV‐2 infection},
journal = {Biomolecular Concepts},
year = {2023},
doi = {10.1515/bmc-2022-0033}
}
EUVIMED